Friday, 17 Aug 2018

You are here

BUILD Study - Baricitinib Shows Rapid Efficacy and X-ray Protection

Baricitinib is an oral, small molecule, once-daily DMARD, that specifically inhibits Janus kinase 1 and 2 and is being developed for use in rheumatoid arthritis. With much of the developmental clinical trials completed, the drug is slated for review and potential approval near the end of the year. 

The baricitinib pivotal studies include the BEGIN study (early RA; MTX naive), BEACON study (TNF incomplete responders [IR]), BEAM study (MTX-IR) and the BUILD study (DMARD-IR). The latter study results were just published in ARD.

The BUILD study was a phase III, 24-week study of 684 RA patients who had failed at least one DMARD. Patients had to be biologic naive and were randomized to receive either placebo or baricitinib (2 or 4 mg) once daily.  The endpoint was the ACR20 response at week 12 and X-ray (TSS) scores at week 24.

Baricitinib showed a significantly greater ACR20 response at week 12 (4 mg 62% vs placebo 39%, p≤0.001).

Not surprisingly, all secondary endpoints were significantly greater with both baricitinib doses. This included radiographic assessments that showed less structural joint damage at week 24 was reduced with baricitinib versus placebo.

Baricitinib was associated with a decrease in neutrophils and increases in low-density and high-density lipoprotein. There were no differences in SAEs or SIEs in treatment groups. There was one case of tuberculosis and one patient with a non-melanoma skin cancer on baricitinib 4 mg.

The 4 mg baricitinib group yielded the most robust results.  It is unclear from data yet reported what the best or approved dose will be.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Success of Stopping Depends on the Biologic

The type of biologic disease-modifying anti-rheumatic drug (DMARD) being used and remission duration were important factors predicting whether remission was maintained among patients with rheumatoid arthritis after cessation of the biologic, a Japanese study found.

IL-1 Suppression May Improve Dilated Cardiomyopathy

 

Interleukin-1 (IL-1) suppression helped reverse symptoms of dilated cardiomyopathy (DCM) for one patient in a case study that may implicate inflammation in the development of the condition.

Defining Refractory RA by Biologic Use

A study from the  British Society for Rheumatology Biologics Register (BSRBR) has shown that biologic refractory disease is seen in at least 6% of patients who have ever received a biologic DMARD (bDMARDs).

IL-23 Inhibitor Fails in Ankylosing Spondylitis

A study of the IL-23 risankizumab in active ankylosing spondylitis (AS) patients failed to show efficacy and did not meet primary efficacy endpoints in a 6-month trial.

Five Barriers to Biosimilar Adoption in the US

A recent Deloitte analysis of the biosimilar market in the USA suggests there are defined obstacles to biosimilar use that must be dealt with, especially as the current administration is seeking to lower drug prices and reduce out-of-pocket costs for US consumers.